Related Experiment Video
Updated: Mar 28, 2026
![Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F60445.jpg&w=3840&q=50)
04:12
Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA
Published on: December 19, 2019
15.7K
Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions
Matthieu Picard1, Leyla Pur1, Joana Caiado1
1Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women's Hospital, Boston, Mass.
The Journal of Allergy and Clinical Immunology
|January 5, 2016
Summary
Risk stratification using hypersensitivity reaction (HSR) severity and skin testing safely guides taxane reintroduction. This approach allows many patients with taxane HSRs to resume regular infusions effectively.
Area of Science:
- Oncology
- Clinical Immunology
- Pharmacology
Background:
- Optimal management for taxane hypersensitivity reactions (HSRs) remains undefined.
- Taxanes are crucial chemotherapeutic agents, necessitating safe reintroduction strategies for patients experiencing HSRs.
Purpose of the Study:
- To evaluate the safety and efficacy of a risk stratification protocol for taxane reintroduction.
- To determine if initial HSR severity and skin testing can guide successful taxane re-exposure.
Main Methods:
- Retrospective analysis of 164 patients with taxane-related HSRs.
- Risk stratification based on HSR severity and skin test results.
- Taxane reintroduction via desensitization, challenge, or regular infusion.
Main Results:
- No severe immediate HSRs occurred during desensitization or challenge.
- 22% of patients successfully resumed regular taxane infusions.
- Negative skin tests and milder initial HSRs predicted successful reintroduction.
Conclusions:
- Risk stratification using HSR severity and skin testing is a safe strategy.
- This approach enables a significant proportion of patients to recontinue taxane therapy.
Related Concept Videos
01:30Drug Toxicity: Allergic Reactions
132
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
132
01:30Hypersensitivities
8.3K
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
8.3K
01:29Hypersensitivity Reactions: Delayed Hypersensitivity Reactions
179
Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
179
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
68
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
01:30Skin Cancer
6.6K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
6.6K
01:31Pulmonary Tuberculosis III
1.4K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
1.4K